Introduction: Currently available drugs against Alzheimer's disease (AD) target cholinergic
and glutamatergic neurotransmissions without affecting the underlying disease process …

ABSTRACT Introduction Currently available Alzheimer's disease (AD) therapeutics are only
symptomatic, targeting cholinergic and glutamatergic neurotransmissions. Several putative …

Alzheimer's disease (AD) is a major form of senile dementia, characterized by progressive
memory and neuronal loss combined with cognitive impairment. AD is the most common …

The beta amyloid (Aβ) protein is a key molecule in the pathogenesis of Alzheimer's disease
(AD). The tendency of the Aβ peptide to aggregate, its reported neurotoxicity, and genetic …

Alzheimer's disease (AD) is one of the most common forms of dementia and has been a
global concern for several years. Due to the multi-factorial nature of the disease, AD has …

Current treatments for patients with Alzheimer's disease aim to improve behavioral,
cognitive, and non-cognitive symptoms. There have been no new drug approvals for …

Pathological, genetic, biochemical and pharmacological studies support the hypothesis that
brain accumulation of oligomeric species of β-amyloid (Aβ) peptides may cause Alzheimer's …

At this time there are no effective methods to alter the disease course in Alzheimer's disease.
All FDA approved interventions are for symptomatic relief only. However, it is an exciting …

Many clinical trials have been conducted in Alzheimer's disease (AD) patients, mainly based
on anti-amyloid drugs. However, the results have not yielded positive results. Ongoing trials …

Neuritic plaques composed of amyloid beta-protein (A beta) are an early and invariant
neuropathological feature of Alzheimer's disease (AD). The current preclinical search for …